These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 3086275)
1. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. Zinner SH; Blaser J J Antimicrob Chemother; 1986 Mar; 17 Suppl A():1-5. PubMed ID: 3086275 [TBL] [Abstract][Full Text] [Related]
2. Interactions of antimicrobial combinations in vitro: the relativity of synergism. Blaser J Scand J Infect Dis Suppl; 1990; 74():71-9. PubMed ID: 2129067 [TBL] [Abstract][Full Text] [Related]
3. In vitro inhibitory and bactericidal activity of cefpiramide and seven antipseudomonal agents against Pseudomonas aeruginosa. Pfaller M; Bale M; Preston T; Howard W; Koontz F Diagn Microbiol Infect Dis; 1986 May; 5(1):17-23. PubMed ID: 3086026 [TBL] [Abstract][Full Text] [Related]
4. [Value of bactericidal curves in the optimal selection of a beta-lactam-aminoglycoside combination on Pseudomonas aeruginosa. In vitro study of 40 strains of Pseudomonas aeruginosa isolated in pediatric intensive care units]. Lambert-Zechovsky N; Bingen E; Guihaire E; Nancy C; Mercier JC; Beaufils F Presse Med; 1986 Dec; 15(46):2309-12. PubMed ID: 2949273 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of newer beta-lactam agents in combination with amikacin against Pseudomonas aeruginosa, Klebsiella pneumoniae, and Serratia marcescens. Meyer RD; Pasiecznik K Diagn Microbiol Infect Dis; 1983 Dec; 1(4):287-93. PubMed ID: 6321092 [TBL] [Abstract][Full Text] [Related]
6. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas. Chan EL; Zabransky RJ Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156 [TBL] [Abstract][Full Text] [Related]
7. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. Oie S; Sawa A; Kamiya A; Mizuno H J Antimicrob Chemother; 1999 Nov; 44(5):689-91. PubMed ID: 10552987 [TBL] [Abstract][Full Text] [Related]
8. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Bustamante CI; Drusano GL; Tatem BA; Standiford HC Antimicrob Agents Chemother; 1984 Nov; 26(5):678-82. PubMed ID: 6440477 [TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years]. Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa. Greenberg RN; Bollinger MR; Alivisatos MR Clin Ther; 1986; 8(6):655-7. PubMed ID: 3098426 [TBL] [Abstract][Full Text] [Related]
11. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker AA; Gürler B J Antimicrob Chemother; 1995 Oct; 36(4):707-11. PubMed ID: 8591946 [TBL] [Abstract][Full Text] [Related]
12. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa]. Yamashiro Y; Ogake N; Takahata M; Minami S Jpn J Antibiot; 2000 Apr; 53(4):194-200. PubMed ID: 10868299 [TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of several antimicrobial agents against selected clinical isolates. Liebowitz LD; Saunders J; Chalkley LJ; Koornhof HJ S Afr Med J; 1990 Apr; 77(8):395-400. PubMed ID: 2109875 [TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activity of imipenem against Pseudomonas and Staphylococcus species. Comparison with thirteen other antimicrobial agents. Cristiano P; Abbate GF; Alagia I; Leonessa V; Giaquinto E; Savioli L Drugs Exp Clin Res; 1985; 11(1):39-48. PubMed ID: 3869802 [TBL] [Abstract][Full Text] [Related]
15. In vitro models for the study of combination antibiotic therapy in neutropenic patients. Zinner SH; Dudley M; Blaser J Am J Med; 1986 Jun; 80(6B):156-60. PubMed ID: 3728526 [TBL] [Abstract][Full Text] [Related]
16. Use of an in-vitro kinetic model to study antibiotic combinations. Zinner SH; Blaser J; Stone BB; Groner MC J Antimicrob Chemother; 1985 Jan; 15 Suppl A():221-6. PubMed ID: 3920181 [TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics. Philippon A Chemioterapia; 1985 Dec; 4(6):424-8. PubMed ID: 3938346 [TBL] [Abstract][Full Text] [Related]
18. In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains. Daschner FD; Steffens A; Langmaack H Chemotherapy; 1979; 25(5):282-5. PubMed ID: 113178 [TBL] [Abstract][Full Text] [Related]
19. Dactimicin, a new aminoglycoside: in vitro activity, post-antibiotic effect and interaction with other antibiotics. Paglia P; Molinari G; Pesce A; Debbia EA Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):639-43. PubMed ID: 2506028 [TBL] [Abstract][Full Text] [Related]
20. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model. Chan E; Zhou S; Srikumar S; Duan W Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]